Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $3.88, but opened at $4.39. Evotec shares last traded at $4.41, with a volume of 16,327 shares.
Analysts Set New Price Targets
EVO has been the subject of a number of analyst reports. Morgan Stanley cut Evotec from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $15.00 to $6.00 in a report on Monday, July 29th. Jefferies Financial Group lowered shares of Evotec from a "buy" rating to a "hold" rating and dropped their price target for the stock from $8.70 to $3.80 in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft downgraded Evotec from a "hold" rating to a "sell" rating in a research note on Thursday, August 8th. Finally, HC Wainwright decreased their price objective on shares of Evotec from $11.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $5.93.
Read Our Latest Analysis on EVO
Evotec Stock Performance
The company has a debt-to-equity ratio of 0.42, a current ratio of 1.83 and a quick ratio of 1.73. The stock's fifty day moving average is $3.46 and its two-hundred day moving average is $4.29.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in EVO. Clear Harbor Asset Management LLC bought a new stake in Evotec during the third quarter worth approximately $104,000. Mediolanum International Funds Ltd bought a new stake in shares of Evotec in the 3rd quarter worth approximately $512,000. Novo Holdings A S acquired a new position in Evotec in the second quarter worth approximately $71,183,000. DCF Advisers LLC lifted its position in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after acquiring an additional 67,156 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Evotec during the 2nd quarter worth $87,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
